Home›Trial›NCT06245213
🔬NCT06245213Phase 2ACTIVE NOT RECRUITING

A Study of ANAVEX3-71 in Adults With Schizophrenia

Study Summary

A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.

Conditions
Schizophrenia
Interventions / Drugs
ANAVEX3-71 oral capsulesPlacebo oral capsules
View on ClinicalTrials.gov ↗
Sponsor
AVXL
Anavex Life Sciences
Neuroscience
D39/100
Study Details
Enrollment71 participants
Primary Completion—
Lead SponsorAnavex Life Sciences Corp.
Data Retrieved2026-04-11 04:06:34.883671+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.